Monumental-6: A Phase 3 Study of Talquetamab plus Pomalidomide or Talquetamab plus Teclistamab Vs Elotuzumab plus Pomalidomide plus Dexamethasone (EPd) or Pomalidomide plus Bortezomib plus Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma Who Received 1-4 Prior Lines of Therapy, Including Lenalidomide and an Anti-CD38 Monoclonal Antibody

被引：0

作者：

Nooka, Ajay K.

Mian, Hira ^{[1
]}

Lee, Cindy ^{[2
]}

Rodriguez-Otero, Paula ^{[3
]}

Kumar, Shaji ^{[4
]}

Einsele, Hermann ^{[5
]}

Vishwamitra, Deeksha ^{[6
]}

Vieyra, Diego ^{[6
]}

Kane, Colleen ^{[6
]}

Kosh, Michele ^{[6
]}

Masterson, Tara J. ^{[6
]}

Heuck, Christoph ^{[7
]}

Kansagra, Ankit ^{[7
]}

Moreau, Philippe ^{[8
]}

机构：

[1] Emory Univ, Winship Canc Inst, Atlanta, GA USA

[2] McMaster Univ, Hamilton, ON, Canada

[3] Royal Adelaide Hosp, Adelaide, Australia

[4] Clin Univ Navarra, Madrid, Spain

[5] Mayo Clin, Div Hematopathol, Rochester, MN USA

[6] Univ Klinikum Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany

[7] Janssen Res & Dev, Spring House, PA USA

[8] Univ Hosp, Nantes, France

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-199752

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：47571 / 47572

页数：2

共 50 条

[1] MonumenTAL-3: Phase 3 Trial of Talquetamab plus Daratumumab ± Pomalidomide Versus Daratumumab plus Pomalidomide plus Dexamethasone in Relapsed/Refractory Multiple Myeloma Following ≥1 Prior Line of Therapy
Cohen, Yael C.
Moreau, Philippe
Tolbert, Jaszianne
Qin, Xiang
Ma, Xuewen
Vieyra, Diego
Langlois, Angelique
Courtoux, Christelle
Terry, William
Pei, Lixia
Heuck, Christoph
Voorhees, Peter
BLOOD, 2022, 140 : 4418 - 4419
[2] Belantamab Mafodotin Plus Pomalidomide and Dexamethasone Vs Pomalidomide Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Subset Analysis in Patients Who Have Received 1 Prior Line of Therapy Including Lenalidomide
Beksac, Meral
Garcia, Esther Gonzalez
Delimpasi, Sosana
Robak, Pawel
Karunanithi, Kamaraj
De Arriba, Felipe
Radocha, Jakub
Kim, Kihyun
Voloshin, Sergey
Zherebtsova, Vera
Osipov, Iurii
Mateos, Maria-Victoria
Zafar, Syed F.
Pour, Ludek
Spicka, Ivan
Suzuki, Kazuhito
Du, Xin
Wilkes, Jodie
Maroj, Brijesh
Morris, Kristin
Ma, Jie
Polinkovsky, Margaret
Wang, Zhaohui
Zhou, Xiaoou L.
Fulci, Giulia
Sule, Neal
Kremer, Brandon
Opalinska, Joanna
Trudel, Suzanne
Dimopoulos, Meletios A.
BLOOD, 2024, 144 : 4731 - 4733
[3] Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM).
Trudel, Suzanne
Beksac, Meral
Pour, Ludek
Delimpasi, Sosana
Quach, Hang
Vorobyev, Vladimir I.
Cavo, Michele
Suzuki, Kazuhito
Robak, Pawel
Morris, Kristin
Phillips-Jones, Amy
Zhou, Xiaoou Linnette
Fulci, Giulia
Sule, Neal
Kremer, Brandon
Opalinska, Joanna
Mateos, Maria-Victoria
Dimopoulos, Meletios Athanasios
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA105 - LBA105
[4] Efficacy and safety of anti-CD38 antibodies in combination with pomalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma
Sato, Tsuyoshi
Asano, Kazuya
Maeta, Takahiro
Kiyohara, Kazuki
Miyajima, Shinri
Otsu, Akihiro
Nishiya, Maki
Sasaki, Ryousei
Okano, Yoshiaki
Kamihara, Satsuki
Kowata, Shugo
Oyake, Tatsuo
Ito, Shigeki
ANNALS OF ONCOLOGY, 2023, 34 : S1446 - S1446
[5] Results From the Randomized Phase 3 DREAMM-8 Study of Belantamab Mafodotin, Pomalidomide, Dexamethasone vs Pomalidomide Plus Bortezomib, Dexamethasone (PVd) in Relapsed/Refractory Multiple Myeloma
Trudel, Suzanne
Beksac, Meral
Pour, Ludek
Delimpasi, Sosana
Vorobyev, Vladimir
Hang Quach
Spicka, Ivan
Radocha, Jakub
Robak, Pawel
Kim, Kihyun
Cavo, Michele
Suzuki, Kazuhito
Morris, Kristin
Pompilus, Farrah
Wilkes, Jodie
Philips-Jones, Amy
Zhou, Xiaoou
Fulci, Giulia
Sule, Neal
Kremer, Brandon
Opalinska, Joanna
Mateos Manteca, Maria-Victoria
Dimopoulos, Meletios
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S39 - S40
[6] DREAMM-8: A phase III study of the efficacy and safety of belantamab mafodotin with pomalidomide and dexamethasone vs pomalidomide plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma
Trudel, Suzanne
Davis, Randy
Lewis, Nicole M.
Bakshi, Kalpana K.
Chopra, Bikramjit
de Oca, Rocio Montes
Ferron-Brady, Geraldine
Eliason, Laurie
Kremer, Brandon E.
Stowell, Delia
Gupta, Ira
Wu, Frank S.
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 177 - 177
[7] A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma
Mikhael, Joseph
Richardson, Paul
Usmani, Saad Z.
Raje, Noopur
Bensinger, William
Karanes, Chatchada
Campana, Frank
Kanagavel, Dheepak
Dubin, Franck
Liu, Qianying
Semiond, Dorothee
Anderson, Kenneth
BLOOD, 2019, 134 (02) : 123 - 133
[8] Phase 1b Study of Daratumumab plus Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (RRMM) with ≥2 Prior Lines of Therapy
Chari, Ajai
Suvannasankha, Attaya
Fay, Joseph
Arnulf, Bertrand
Kaufman, Jonathan L.
Ifthikharuddin, Jainulabdeen
Weiss, Brendan M.
Krishnan, Amrita
Lentzsch, Suzanne
Comenzo, Ray
Wang, Jim
Masterson, Tara
Nottage, Kerri
Schecter, Jordan
Chiu, Christopher
Khokhar, Nushmia
Ahmadi, Tahamtan
Lonial, Sagar
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E14 - E15
[9] Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study
Kelly, Kevin R.
Ailawadhi, Sikander
Siegel, David S.
Heffner, Leonard T.
Somlo, George
Jagannath, Sundar
Zimmerman, Todd M.
Munshi, Nikhil C.
Madan, Sumit
Chanan-Khan, Asher
Lonial, Sagar
Chandwani, Suraj
Minasyan, Ashot
Ruehle, Markus
Barmaki-Rad, Farima
Abdolzade-Bavil, Afsaneh
Rharbaoui, Faiza
Herrmann-Keiner, Eva
Haeder, Thomas
Wartenberg-Demand, Andrea
Anderson, Kenneth C.
LANCET HAEMATOLOGY, 2021, 8 (11): : E794 - E807
[10] HORIZON (OP-106): Melflufen Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Pomalidomide and/or an Anti-CD38 Monoclonal Antibody - Primary and Subgroup Analysis
Richardson, Paul
Oriol, Albert
Larocca, Alessandra
Blade, Joan
Cavo, Michele
Rodriguez-Otero, Paula
Leleu, Xavier
Norkin, Maxim
Nadeem, Omar
Hiemenz, John
Hassoun, Hani
Touzeau, Cyrille
Alegre, Adrian
Paner, Agne
Maisel, Christopher
Mazumder, Amitabha
Raptis, Anastasios
Puig, Noemi
Byrne, Catriona
Mateos, Maria-Victoria
AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 : S27 - S28

← 1 2 3 4 5 →